Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Arthritis, Rheumatoid 2

Interventions

Methotrexate 10Adalimumab 6tocilizumab 5Rituximab 5olokizumab 4tofacitinib 3Etanercept 3golimumab 2RC-18 2Abatacept 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1baricitinib 1andecaliximab 1Tumor Necrosis Factor Inhibitors 1TACI receptor-IgG Fc fragment fusion protein 1Sulfasalazine 1Pharmaceutical Preparations 1Leflunomide 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1ISIS104838 1Hydroxychloroquine 1Folic Acid 1Double-Blind Method 1Chloroquine 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Arthritis, Rheumatoid × Abatacept × Clear all
NCT01350804 2016-05-23

NURTURE 1

Novartis

Phase 3 Completed
551 enrolled 19 charts

Arthritis, Rheumatoid

NCT00048581 2011-11-21

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

Bristol-Myers Squibb

Phase 3 Completed
738 enrolled 84 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡